| P/E (FY) | — | Sales (TTM) | $10.0M |
| Earnings (TTM) | -$425.2M | ROE | −136.22% |
| Net Margin | −3777.37% | ROIC | — |
| Debt / Equity | 0.32 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Zenas BioPharma is a clinical-stage biopharma company developing and commercializing immunology-based therapies. Its lead candidate, obexelimab, is a bifunctional monoclonal antibody binding CD19 and FcyRIIb for immunology and inflammation diseases including IgG4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company is also developing ZB002, an anti-TNFa antibody; ZB004, a CTLA-4-Ig fusion protein; and ZB001, an anti-IGF-1R antibody. It is headquartered in Waltham, Massachusetts.
| Market Cap | $2.04B | Trading Days | 1672 |
| 52W High | 44.60 |
| 52W Low | 13.50 |
| % Off High | −27.60% |
| YTD | −11.07% | 1Y | 96.29% |
| 3Y | 77.91% | 5Y | 77.91% |
| 10Y | 42.50% | Since incept. (ann.) | 4.39% |
Single Reportable 100%
| Ann. Volatility (1Y) | 111.54% | Ann. Volatility (3Y) | 107.28% |
| Sharpe (1Y) | 1.24 | Sharpe (3Y) | 0.86 |
| Max Drawdown (1Y) | −64.79% | Max Drawdown (3Y) | −74.96% |
| Beta (3Y, vs SPY) | −1.14 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| PVLA | PALVELLA THERAPEUTICS, INC. | $2.05B | — |
| VRDN | Viridian Therapeutics, Inc.\DE | $2.01B | — |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.07B | 13.2 |
| RAPP | Rapport Therapeutics, Inc. | $2.01B | — |
| BHVN | Biohaven Ltd. | $2.07B | — |
| IMUX | IMMUNIC, INC. | $2.08B | — |
| URGN | UroGen Pharma Ltd. | $1.99B | — |
| ANIP | ANI PHARMACEUTICALS INC | $1.98B | 24.4 |
| SION | Sionna Therapeutics, Inc. | $2.10B | — |
| PGEN | PRECIGEN, INC. | $1.97B | — |
| AGIO | AGIOS PHARMACEUTICALS, INC. | $2.14B |
| AUPH | Aurinia Pharmaceuticals Inc. | $1.92B | 7.2 |